AVACTA GROUP PLC: FARIDOXORUBICIN TREATMENT RESULTS IN NEAR DOUBLING OF PROGRESSION-FREE SURVIVAL AND CLINICALLY MEANINGFUL TUMOR SHRINKAGE IN MOST PATIENTS WITH SALIVARY GLAND CANCERS

Reuters · 1d ago

Please log in to view news